FR3077574B1 - Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. - Google Patents
Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. Download PDFInfo
- Publication number
- FR3077574B1 FR3077574B1 FR1851026A FR1851026A FR3077574B1 FR 3077574 B1 FR3077574 B1 FR 3077574B1 FR 1851026 A FR1851026 A FR 1851026A FR 1851026 A FR1851026 A FR 1851026A FR 3077574 B1 FR3077574 B1 FR 3077574B1
- Authority
- FR
- France
- Prior art keywords
- directed against
- antibodies directed
- receptor subtype
- endothelin receptor
- against endothelin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000010180 Endothelin receptor Human genes 0.000 title abstract 2
- 108050001739 Endothelin receptor Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1851026A FR3077574B1 (fr) | 2018-02-07 | 2018-02-07 | Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. |
US16/967,763 US20220089755A1 (en) | 2018-02-07 | 2019-02-04 | Antibody against the endothelin receptor subtype a, and uses thereof |
JP2020542857A JP7456930B2 (ja) | 2018-02-07 | 2019-02-04 | エンドセリン受容体サブタイプaに対する抗体及びその使用 |
PCT/FR2019/050245 WO2019155151A2 (fr) | 2018-02-07 | 2019-02-04 | Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations |
EP19744751.9A EP3735428A2 (fr) | 2018-02-07 | 2019-02-04 | Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1851026 | 2018-02-07 | ||
FR1851026A FR3077574B1 (fr) | 2018-02-07 | 2018-02-07 | Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3077574A1 FR3077574A1 (fr) | 2019-08-09 |
FR3077574B1 true FR3077574B1 (fr) | 2022-04-01 |
Family
ID=62017513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1851026A Active FR3077574B1 (fr) | 2018-02-07 | 2018-02-07 | Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220089755A1 (fr) |
EP (1) | EP3735428A2 (fr) |
JP (1) | JP7456930B2 (fr) |
FR (1) | FR3077574B1 (fr) |
WO (1) | WO2019155151A2 (fr) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO2007095353A2 (fr) * | 2006-02-14 | 2007-08-23 | Geisinger Clinic | Récepteurs gpcr utilisés comme cibles pour l'angiogenèse |
JP2008280266A (ja) | 2007-05-09 | 2008-11-20 | Sekisui Chem Co Ltd | モノクローナル抗体 |
FR2965810B1 (fr) | 2010-10-06 | 2012-12-28 | Commissariat Energie Atomique | Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations |
CN103728454B (zh) * | 2012-10-10 | 2016-05-18 | 吴庄民 | 基于表位抗原肽的抗内皮素受体a抗体酶联免疫试剂盒及其应用 |
CN111018987B (zh) * | 2014-12-05 | 2023-11-21 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
TWI826351B (zh) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧(杭州)生物醫藥有限公司 | R抗體,其藥物組合物及其應用 |
FR3053042B1 (fr) | 2016-06-24 | 2018-08-10 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations |
-
2018
- 2018-02-07 FR FR1851026A patent/FR3077574B1/fr active Active
-
2019
- 2019-02-04 WO PCT/FR2019/050245 patent/WO2019155151A2/fr unknown
- 2019-02-04 EP EP19744751.9A patent/EP3735428A2/fr active Pending
- 2019-02-04 JP JP2020542857A patent/JP7456930B2/ja active Active
- 2019-02-04 US US16/967,763 patent/US20220089755A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019155151A3 (fr) | 2019-12-12 |
WO2019155151A2 (fr) | 2019-08-15 |
JP2021513345A (ja) | 2021-05-27 |
US20220089755A1 (en) | 2022-03-24 |
FR3077574A1 (fr) | 2019-08-09 |
EP3735428A2 (fr) | 2020-11-11 |
JP7456930B2 (ja) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34524B1 (fr) | Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) | |
MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
MA31984B1 (fr) | Formulation d'anticorps | |
MA42622B1 (fr) | Agents de liaison à tigit et leurs utilisations | |
SG10201914119TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
MA34749B1 (fr) | Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations | |
MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
MA30497B1 (fr) | Anticorps et immunco-conjugues, et leurs utilisations. | |
MA30910B1 (fr) | Anticorps et immunoconjugues, et leurs utilisations | |
MA44334A (fr) | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll | |
MA39061A1 (fr) | Modulateurs d'aplnr et leurs utilisations | |
MA38632B1 (fr) | Anticorps anti-récepteur de transferrine et procédés d'utilisation | |
MA32566B1 (fr) | Anticorps neutralisant les cytomégalovirus humains et leurs utilisations | |
MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
MA30345B1 (fr) | Formulation d'anticorps monoclonal humain anti-igf-1r | |
MA35620B1 (fr) | Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions | |
MA35928B1 (fr) | Thérapie combinée d'anticorps contre le csf -1r humain et ses utilisations | |
MA30922B1 (fr) | Anticorps d'agonistes de trkb et leurs utilisations | |
MA49727A (fr) | Anticorps et polypeptides dirigés contre cd127 | |
MA37407A1 (fr) | Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine | |
MA43717B1 (fr) | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci | |
MA39909B1 (fr) | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer | |
MA31435B1 (fr) | Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2 | |
FR2897063B1 (fr) | Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications. | |
WO2007033140A3 (fr) | Antagonistes prok2 et leurs procedes d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20190809 |
|
TQ | Partial transmission of property |
Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERG, FR Effective date: 20191217 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR Effective date: 20191217 Owner name: UNIVERSITE DE MONTPELLIER, FR Effective date: 20191217 Owner name: UNIVERSITE PARIS-DIDEROT - PARIS 7, FR Effective date: 20191217 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
CD | Change of name or company name |
Owner name: UNIVERSITE PARIS CITE, FR Effective date: 20230621 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR Effective date: 20230621 Owner name: UNIVERSITE DE MONTPELLIER, FR Effective date: 20230621 Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERG, FR Effective date: 20230621 |
|
TQ | Partial transmission of property |
Owner name: UNIVERSITE PARIS CITE, FR Effective date: 20230621 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR Effective date: 20230621 Owner name: UNIVERSITE DE MONTPELLIER, FR Effective date: 20230621 Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERG, FR Effective date: 20230621 |
|
PLFP | Fee payment |
Year of fee payment: 7 |